A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2027, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MODD SEC filings page.
This page shows Modular Medical, Inc. (MODD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The development-stage business is increasing R&D and capital spending while financing inflows fund ongoing cash needs.
FY2026’s net loss was$28.2M while operating cash flow was-$23.8M , showing little conversion cushion between accounting loss and cash loss. Free cash flow reached-$27.7M after$3.9M of investing outflow, so reinvestment added to cash consumption rather than obscuring it.
R&D rose
Financing cash inflow was
Financial Health Signals
We do not publish a peer-relative financial health score for Modular Medical, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Modular Medical, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Modular Medical, Inc. reported a net loss of $28.2M while operations used $23.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Modular Medical, Inc.'s EBITDA was -$6.7M in Q2 2027, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Modular Medical, Inc. reported a net loss of $7.1M in Q2 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Modular Medical, Inc. earned -$0.90 per diluted share (EPS) in Q2 2027. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2027.
Cash & Balance Sheet
Modular Medical, Inc. recorded an outflow of $6.4M in free cash flow in Q2 2027, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Modular Medical, Inc. held $5.1M in cash as of Q2 2027; no long-term debt figure is on record for that period.
Not reported for Q2 2027.
Margins & Returns
Modular Medical, Inc.'s quarterly ROE was -62.2% in Q2 2027: one quarter's net income over shareholder equity, not annualized. This is up 26.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.
Not reported for Q2 2027.
Not reported for Q2 2027.
Not reported for Q2 2027.
Capital Allocation
Modular Medical, Inc. invested $3.9M in research and development in Q2 2027. This represents a decrease of 29.8% from the same quarter a year earlier. Against the prior quarter it is down 10.2%.
Modular Medical, Inc. invested $88K in capex in Q2 2027, funding long-term assets and infrastructure. This represents a decrease of 88.6% from the same quarter a year earlier. Against the prior quarter it is down 87.2%.
Not reported for Q2 2027.
MODD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $3.9M-29.8% | $4.4M-14.9% | $3.8M-2.4% | $5.4M+40.3% | $5.6M+51.1% | $5.1M+60.2% | $3.9M+26.4% | $3.9M+0.4% |
| SG&A Expenses | $3.2M+43.8% | $2.2M+29.8% | $1.8M+76.9% | $1.8M+83.7% | $2.2M+72.8% | $1.7M+64.5% | $1.0M-13.5% | $1.0M-30.0% |
| Operating Income | -$7.1Mn/m | -$6.5Mn/m | -$5.7Mn/m | -$7.2Mn/m | -$7.8Mn/m | -$6.8Mn/m | -$5.0Mn/m | -$4.9Mn/m |
| EBITDA | -$6.7Mn/m | -$6.0Mn/m | -$5.2Mn/m | -$6.8Mn/m | -$7.4Mn/m | -$6.4Mn/m | -$4.7Mn/m | -$4.6Mn/m |
| Income Tax | $2K0.0% | N/A | N/A | N/A | $2K0.0% | N/A | N/A | N/A |
| Net Income | -$7.1Mn/m | -$6.5Mn/m | -$6.4Mn/m | -$7.4Mn/m | -$7.8Mn/m | -$6.7Mn/m | -$4.9Mn/m | -$4.8Mn/m |
| EPS (Basic) | -$0.90 | -$1.19 | N/A | -$3.30 | -$4.21 | -$3.70 | -$3.60n/m | -$3.90 |
| EPS (Diluted) | -$0.90 | -$1.19 | N/A | -$3.30 | -$4.21 | -$3.70 | -$3.60n/m | -$3.90 |
| Diluted Shares (Avg) | 8M | 5M | N/A | 2M | 2M | 2M | N/A | 1M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
MODD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'26Filing | Q1'26Filing | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.7M-1.8% | $12.3M-13.5% | $14.8M-20.8% | $10.3M-15.6% | $13.0M+47.9% | $14.2M+40.7% | $18.7M+35.7% | $12.1M+96.0% |
| Current Assets | $5.9M-1.4% | $4.8M-41.6% | $7.5M-44.2% | $3.5M-52.7% | $5.9M+42.4% | $8.3M+53.4% | $13.5M+39.4% | $7.3M+213.0% |
| Cash & Equivalents | $5.1M-4.1% | $3.9M-47.9% | $6.9M-47.0% | $2.9M-58.0% | $5.3M+36.6% | $7.5M+48.9% | $13.1M+41.8% | $7.0M+241.3% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $1.3M-68.7% | $1.5M-36.0% | $1.9M+13.0% | $4.4M+132.0% | $4.2M+126.7% | $2.3M+13.2% | $1.7M-27.0% | $1.9M-19.8% |
| Current Liabilities | $1.3M-67.5% | $1.5M-27.4% | $1.9M+48.1% | $2.2M+57.6% | $4.0M+225.1% | $2.0M+52.8% | $1.3M-13.1% | $1.4M-3.9% |
| Non-Current Liabilities | $0-100.0% | $0-100.0% | $0-100.0% | $2.2M+336.3% | $161K-73.6% | $278K-61.1% | $393K-51.9% | $504K-44.9% |
| Total Equity | $11.4M+30.2% | $10.8M-9.1% | $13.0M-24.1% | $5.9M-42.7% | $8.8M+26.8% | $11.8M+47.7% | $17.1M+48.0% | $10.3M+166.9% |
| Retained Earnings | -$126.6Mn/m | -$119.5Mn/m | -$113.0Mn/m | -$106.6Mn/m | -$99.2Mn/m | -$91.5Mn/m | -$84.8Mn/m | -$79.8Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
MODD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.3Mn/m | -$6.0Mn/m | -$5.8Mn/m | -$7.2Mn/m | -$5.4Mn/m | -$5.4Mn/m | -$4.3Mn/m | -$4.1Mn/m |
| Depreciation & Amortization | $447K+14.3% | $501K+22.2% | $441K+35.3% | $430K+53.0% | $391K+50.4% | $410K+109.2% | $326K+128.0% | $281K+116.2% |
| Stock-Based Compensation | N/A | $447K-38.3% | N/A | $2K-60.0% | $4K-55.6% | $724K+35.3% | N/A | $5K-54.5% |
| Capital Expenditures | $88K-88.6% | $688K-26.3% | $1.0M+6.0% | $1.2M+125.5% | $771K+378.9% | $934K+10.9% | $948K+96.3% | $542K+8.6% |
| Free Cash Flow | -$6.4Mn/m | -$6.7Mn/m | -$6.8Mn/m | -$8.4Mn/m | -$6.2Mn/m | -$6.3Mn/m | -$5.3Mn/m | -$4.6Mn/m |
| Investing Cash Flow | -$88Kn/m | -$688Kn/m | -$1.0Mn/m | -$1.2Mn/m | -$771Kn/m | -$934Kn/m | -$948Kn/m | -$542Kn/m |
| Financing Cash Flow | $7.5M+89.8% | $3.6M+396.3% | $10.8M-4.8% | $6.0M-22.4% | $4.0M+43.6% | $733K+249.0% | $11.4M+1.8% | $7.7M+4171.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MODD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -62.2%+26.6pp | -60.3%-3.7pp | -49.3%-20.5pp | -125.2%-78.3pp | -88.8%-17.2pp | -56.6%-5.0pp | -28.9%+8.3pp | -46.8%+90.2pp |
| Return on Assets | -55.8%+4.3pp | -52.9%-5.6pp | -43.1%-16.8pp | -71.7%-32.2pp | -60.0%-3.5pp | -47.3%-6.2pp | -26.3%+4.7pp | -39.5%+45.5pp |
| Current Ratio | 4.46+3.0x | 3.25-0.8x | 4.03-6.7x | 1.59-3.7x | 1.47-1.9x | 4.040.0x | 10.69+4.0x | 5.30+3.7x |
| Liabilities-to-Equity | 0.12-0.4x | 0.14-0.1x | 0.140.0x | 0.74+0.6x | 0.48+0.2x | 0.20-0.1x | 0.10-0.1x | 0.18-0.4x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Modular Medical, Inc. MODD | FY2026 | N/A | -$28.2M | N/A | $18.1M | — |
| Picard Medical, Inc. PMI | FY2025 | N/A | -$27.0M | N/A | $17.8M | — |
| CVRx, Inc. CVRX | FY2025 | $56.7M | -$53.3M | -94.1% | $17.5M | 53/100 |
| SANUWAVE Health, Inc. SNWV | FY2025 | $44.1M | $11.8M | 26.8% | $15.6M | 59/100 |
| Cytosorbents Corp. CTSO | FY2025 | $37.1M | -$8.2M | -22.1% | $15.3M | 47/100 |
| Nano-X Imaging Ltd NNOX | FY2025 | $13.0M | -$75.0M | N/A | $25.4M | 56/100 |
Where Modular Medical, Inc. Ranks
Frequently Asked Questions
No, Modular Medical, Inc. (MODD) reported a net loss of $27.3M over the trailing 12 months to September 30, 2026. In fiscal year 2026 it reported a net loss of $28.2M.
Modular Medical, Inc. (MODD) had EBITDA of -$25.9M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
Modular Medical, Inc. (MODD) has a return on equity of -217.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
Modular Medical, Inc. (MODD) recorded an outflow of $27.7M in free cash flow during fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Modular Medical, Inc. (MODD) recorded an outflow of $23.8M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
Modular Medical, Inc. (MODD) had $14.8M in total assets as of fiscal year 2026, including both current and long-term assets.
Modular Medical, Inc. (MODD) invested $3.9M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
Modular Medical, Inc. (MODD) invested $20.0M in research and development during fiscal year 2026.
Modular Medical, Inc. (MODD) had a current ratio of 4.03 as of fiscal year 2026, which is generally considered healthy.
Modular Medical, Inc. (MODD) had a liabilities-to-equity ratio of 0.14 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
Modular Medical, Inc. (MODD) had a return on assets of -190.4% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
Modular Medical, Inc. (MODD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $18.1M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Modular Medical, Inc. (MODD) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $18.1M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2026, Modular Medical, Inc. (MODD) held $6.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.8M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Modular Medical, Inc. (MODD) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Modular Medical, Inc. (MODD) reported a net loss of $28.2M while operations used $23.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.